Results for the year ended 31 March 2026

AI SummaryClose X

ECO Animal Health Group PLC reported a 10% increase in revenue to £87.5 million for the year ended 31 March 2026, with adjusted EBITDA rising 16% to £8.5 million, exceeding market expectations. The company saw strong revenue growth of 22% in North America and 15% in Latin America, while gross margin improved to 49% due to disciplined cost control. Research and development expenditure increased to £8.8 million, and profit before tax grew by 35% to £5.4 million, resulting in earnings per share of 3.26p. Post-year-end, the company successfully launched its poultry vaccine ECOVAXXIN® MS in the EU, with further approvals anticipated for up to nine products in the next five to six years.

Disclaimer*

UK 100

Latest directors dealings